Acquiring Company
Halozyme Therapeutics
Acquired Company
Hypercon
San Diego
North BrabantManufacturingBiotechnologyHealth CarePharmaceuticalBiopharmaBiotechnologyHealth CareDescription
Halozyme Therapeutics has agreed to acquire Hypercon and several biotech startups, enhancing its drug delivery capabilities. This acquisition extends Halozyme’s intellectual property coverage into the 2040s. The deal aligns with the company's ambition to grow its platform and expand usage of its technologies in healthcare. This strategic move reflects a commitment to innovation in drug delivery methods.
Quick answer
Halozyme Therapeutics is acquiring Hypercon, announced March 4, 2026. Halozyme Therapeutics is based in San Diego, California, United States.
- How much did Halozyme Therapeutics pay for Hypercon?
- The deal value was not disclosed.
- What does Halozyme Therapeutics do?
- Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.
- Where are Halozyme Therapeutics and Hypercon based?
- Halozyme Therapeutics is based in San Diego, California, United States. Hypercon is based in North Brabant, Netherlands.
- Who are the decision-makers at Halozyme Therapeutics?
- Fundz holds 3 contacts at Halozyme Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Eli Lilly to acquire Centessa Pharmaceuticals (March 31, 2026)
- Kopran Limited to merge with Kopran Laboratories Limited (February 27, 2026)
- GSK to acquire 35Pharma for HS235 development (February 25, 2026)
- Anlon Healthcare acquires Remember India Health Links (April 16, 2026)
- Garda Therapeutics to acquire Assertio for $125.1M, $125M (April 8, 2026)
- Merck acquires JSR Life Sciences' chromatography business (April 2, 2026)
Who to call at Halozyme Therapeutics, and when
When Halozyme Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Halozyme Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Halozyme Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Halozyme Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Halozyme Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Hypercon?
Hypercon was acquired by Halozyme Therapeutics, based in San Diego. The deal was reported on March 4, 2026. Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. Halozyme Therapeutics is publicly traded (HALO) and operates in Manufacturing.
When did Halozyme Therapeutics acquire Hypercon?
Halozyme Therapeutics's acquisition of Hypercon was reported on March 4, 2026. Halozyme Therapeutics has agreed to acquire Hypercon and several biotech startups, enhancing its drug delivery capabilities. This acquisition extends Halozyme’s intellectual property coverage into the 2040s. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Hypercon do?
Hypercon is a biotech company involved in innovative therapeutic solutions. It focuses on enhancing drug delivery methods, making treatments more effective and accessible. It is privately held, operating in Biotechnology, and is based in North Brabant.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.